AllSci News
Ipsen closes USD 450m deal for Kartos and myelofibrosis asset navtemadlin
Ipsen (Euronext: IPN) has completed its acquisition of Kartos Therapeutics, the Redwood City, California-based clinical-stage company whose sole disclosed...
Hansa aims for secondary US listing ahead of FDA decision on kidney transplant therapy
Sweden-based Hansa Biopharma AB (Nasdaq Stockholm: HNSA), a commercial-stage immunology company with an EU-approved enzyme therapy and a pending US FDA...
China's CDE launches PIONEER Program for cell and gene therapy products
Category: Regulatory Policy | Regulatory Body: CDE (Center for Drug Evaluation, NMPA) | Geography: China | Instrument: Initiative launch
Simcere takes on Beyfortus with China rights deal for long-acting RSV antibody
Simcere Pharmaceutical Group (HKEX: 2096) has secured exclusive commercialization rights in Greater China for kulaiweibai monoclonal antibody, a...
Amylyx ups fundraising target to USD 500m after avexitide's Phase III win in hypoglycemia
Cambridge, Massachusetts-based Amylyx Pharmaceuticals (Nasdaq: AMLX) announced the pricing of an upsized underwritten public offering of common stock,...
Lupin expands presbyopia footprint with EUR 75m Yuvezzi licensing deal across Europe
Lupin Limited (BSE: 500257, NSE: LUPIN) and Tenpoint Therapeutics Holding Limited have announced an exclusive licensing agreement granting Lupin's European...
FDA grants Fast Track Designation to Rein's LTI-03 for idiopathic pulmonary fibrosis
Austin, Texas-based Rein Therapeutics (Nasdaq: RNTX) announced that the US FDA has granted Fast Track Designation to LTI-03, a first-in-class inhaled...
FDA grants Nuvation fast-track status for safusidenib in IDH1-mutant glioma
New York-based Nuvation Bio Inc. (NYSE: NUVB) announced that the US FDA has granted Fast Track Designation to safusidenib, an oral, brain-penetrant,...
UroGen takes first step beyond urothelial cancer with IntraGel deal
UroGen Pharma (Nasdaq: URGN) has signed a collaboration and equity investment agreement with Israel-based IntraGel Therapeutics, committing up to USD 7...
Hengrui's licancopan wins China PNH approval after outperforming eculizumab in Phase III
China's National Medical Products Administration (NMPA) has approved Licancopan fumarate (HRS-5965) capsules, developed by Chengdu Suncadia Medicine Co.,...
AC Immune's NLRP3 inhibitor reaches brain with safety intact in first human study
AC Immune SA (Nasdaq: ACIU) reported that its oral NLRP3 inflammasome inhibitor ACI-19764 was safe and well-tolerated across single and multiple ascending...
Stanford-led team engineers synthetic transcription factors to boost CAR-T cells
A combinatorial protein-engineering platform that assembles novel transcription factors from shuffled natural domains can substantially improve the...
Peking University team develops delayed STING activation strategy for mRNA cancer vaccines
A preclinical platform that chemically delays activation of the STING innate immune pathway until after antigen translation has begun produced stronger...
Amgen exits TScan TCR discovery collaboration tied to over USD 500m in milestones
Amgen has notified TScan Therapeutics (Nasdaq: TCRX) of its election to terminate the research collaboration and license agreement the two companies entered...
Kynexis takes Series A to EUR 97 million as Novartis backs schizophrenia cognition drug
Netherlands-based Kynexis announced the closing of a EUR 40 million (USD 45 million) extension to its Series A, bringing total Series A financing to EUR 97...
The AllSci Brief
Free, systematic R&D and deal news. Daily.